Home » Stocks » CLBS

Caladrius Biosciences, Inc. (CLBS)

Stock Price: $1.47 USD -0.02 (-1.34%)
Updated May 18, 2021 1:58 PM EDT - Market open
Market Cap 86.27M
Revenue (ttm) n/a
Net Income (ttm) -12.22M
Shares Out 42.12M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $1.47
Previous Close $1.49
Change ($) -0.02
Change (%) -1.34%
Day's Open 1.47
Day's Range 1.44 - 1.52
Day's Volume 563,877
52-Week Range 1.25 - 4.89

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of -111.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the...

1 week ago - Zacks Investment Research

BASKING RIDGE, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

2 weeks ago - GlobeNewsWire

Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Caladrius Biosciences, Inc. (CLBS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago - Zacks Investment Research

BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

2 months ago - GlobeNewsWire

Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing

2 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

2 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

3 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

3 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

3 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

3 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

3 months ago - GlobeNewsWire

Caladrius Biosciences is focused on treating coronary microvascular dysfunction. The condition is most common among women, especially after menopause.

3 months ago - InvestorPlace

Initiation of the Phase 2b FREEDOM trial represents the next step in development of CLBS16 as a potential breakthrough treatment for the millions of sufferers of CMD in the U.S., most of whom are women

3 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

4 months ago - GlobeNewsWire

The short term investor may want to consider this trio of companies

Other stocks mentioned: JT, RMED
4 months ago - GuruFocus

BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

5 months ago - GlobeNewsWire

The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

6 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

6 months ago - GlobeNewsWire

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

BASKING RIDGE, N.J. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

6 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

6 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

6 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

6 months ago - GlobeNewsWire

Patient screening begins immediately at NYU Langone Health

7 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

7 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

7 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developme...

8 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developme...

8 months ago - GlobeNewsWire

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

BASKING RIDGE, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developmen...

9 months ago - GlobeNewsWire

BASKING RIDGE, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developmen...

9 months ago - GlobeNewsWire

BASKING RIDGE, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developmen...

9 months ago - GlobeNewsWire

Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

BASKING RIDGE, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

11 months ago - GlobeNewsWire

Single administration of CLBS16 durably improves heart function and symptoms in patients with coronary microvascular dysfunction Single administration of CLBS16 durably improves heart function and sympt...

1 year ago - GlobeNewsWire

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developme...

1 year ago - GlobeNewsWire

BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the developme...

1 year ago - GlobeNewsWire

FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory ...

1 year ago - GlobeNewsWire

BASKING RIDGE, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that it has finalized an agreement to sell $10.9 mill...

1 year ago - GlobeNewsWire

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Single administration of CLBS16 durably improves heart function and symptoms with no cell-related adverse events

1 year ago - GlobeNewsWire

Caladrius Biosciences' (CLBS) CEO David Mazzo on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Top Ranked Momentum Stocks to Buy for July 25th

Other stocks mentioned: FNV, GNTX, POL
1 year ago - Zacks Investment Research

Caladrius Biosciences, Inc.'s (CLBS) CEO David Mazzo on Q1 2019 Earnings Conference Call Transcript

2 years ago - Seeking Alpha

Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2018 Earnings Conference Call Transcript

2 years ago - Seeking Alpha

About CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dys... [Read more...]

Industry
Biotechnology
Founded
1980
CEO
David Mazzo
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
CLBS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CLBS stock is "Buy." The 12-month stock price forecast is 8.67, which is an increase of 489.80% from the latest price.

Price Target
$8.67
(489.80% upside)
Analyst Consensus: Buy